Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L, De Pas T, Pagan E, Minucci S, Catania C, Digiacomo N, Cocorocchio E, Laszlo D, Di Muzio A, Barigazzi C, Stucchi E, De Grandi L, Stucchi S, Viale G, Gelber RD, Bagnardi V, Conforti F. Pala L, et al. Among authors: laszlo d. Semin Oncol. 2023 Feb-Apr;50(1-2):34-39. doi: 10.1053/j.seminoncol.2023.03.003. Epub 2023 Mar 21. Semin Oncol. 2023. PMID: 36967333 Review.
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
Conforti F, Pala L, De Pas T, Zattarin E, Catania C, Cocorocchio E, Rossi G, Laszlo D, Colleoni M, Zambelli A, Hortobagyi GN, Cortes J, Piccart MJ, Dowsett M, Gelber RD, Viale G. Conforti F, et al. Among authors: laszlo d. Clin Cancer Res. 2024 Mar 15;30(6):1093-1103. doi: 10.1158/1078-0432.CCR-23-1836. Clin Cancer Res. 2024. PMID: 37906083
"Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.".
Pala L, Sala I, Pagan E, De Pas T, Zattarin E, Catania C, Cocorocchio E, Rossi G, Laszlo D, Ceresoli G, Canzian J, Valenzi E, Bagnardi V, Conforti F. Pala L, et al. Among authors: laszlo d. Breast. 2024 Feb;73:103672. doi: 10.1016/j.breast.2024.103672. Epub 2024 Jan 19. Breast. 2024. PMID: 38244459 Free PMC article.
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
Zannetti BA, Saraceni F, Cellini C, Fabbri E, Monaco F, Guarini A, Laszlo D, Martino M, Olivieri A, Imola M, Tosi P, Chiarucci M, Zuffa E, Lanza F. Zannetti BA, et al. Among authors: laszlo d. Transplant Cell Ther. 2021 Mar;27(3):244.e1-244.e8. doi: 10.1016/j.jtct.2020.12.009. Epub 2021 Jan 28. Transplant Cell Ther. 2021. PMID: 33781522 Free article.
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.
Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, Skrypets T, Horwitz SM, De Souza CA, Radford JA, Bobillo S, Prates MV, Ferreri AJM, Chiattone C, Spina M, Vose JM, Chiappella A, Laszlo D, Marino D, Stelitano C, Federico M. Shustov A, et al. Among authors: laszlo d. Blood Adv. 2021 Feb 9;5(3):640-648. doi: 10.1182/bloodadvances.2020001581. Blood Adv. 2021. PMID: 33560375 Free PMC article.
A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, Magarò A, Caime A, Menna S, Lionetti MT, Bertolini F. Laszlo D, et al. Transfus Apher Sci. 2020 Oct;59(5):102819. doi: 10.1016/j.transci.2020.102819. Epub 2020 May 25. Transfus Apher Sci. 2020. PMID: 32499108
139 results